Economic TimesSanofi, Regeneron Must Assess Brain Risk in Cholesterol Drug (2)BusinessweekRegeneron Pharmaceuticals Inc. (REGN:US) and Sanofi (SAN) and must assess how their experimental cholesterol drug affects brain function after U.S. regulators learned of adverse events associated with this new class of medicines. The companies don’t …FDA Advises of Adverse Effects from New Cholesterol DrugsWall Street JournalFDA Sprinkles Some Rain On the PCSK9 Inhibitor ParadeForbesUPDATE 1-US FDA asks Sanofi, Regeneron to assess cholesterol drug’s …ReutersFierceBiotechall 16 news articles …read more
Via: Google USA
Sanofi, Regeneron Must Assess Brain Risk in Cholesterol Drug (2) - Businessweek
Real Estate of Cebu
